TY - JOUR AU - Passiglia, Francesco AU - Bironzo, Paolo AU - Scagliotti, Giorgio V. PY - 2019 TI - First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer? JF - Translational Lung Cancer Research; Vol 8, No 4 (August 31, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - In The New England Journal of Medicine , Paz-Ares and colleagues published the results of KEYNOTE-407, a randomized phase III placebo-controlled trial, investigating the addition of pembrolizumab or placebo to first-line carboplatin-taxane chemotherapy, in patients with advanced squamous non-small cell lung cancer (NSCLC) (1). The study met its co-primary end-points, since immune-chemotherapy combination led to a significant longer overall survival (OS) and progression-free survival (PFS) as compared to placebo combination. UR - https://tlcr.amegroups.org/article/view/28462